H eart failure (HF) is a syndrome, the progressive nature of which is well recognized. The guidelines emphasize the importance of its early, preclinical stages and divide the disorder into 4 stages (1). Two stages (A and B) are asymptomatic.
stages of HF are poorly understood, which hinders prevention.
The dearth of data on the subject, the magnitude of the public health burden of HF, and the unfavorable outcomes of HF, once clinically manifest, all constitute a robust rationale to focus on ALVD. In this issue of the JACC: Heart Failure, Echouffo-Tcheugui et al.
(2) report a systematic overview and meta-analysis on the important and challenging topic of progression from ALVD to overt HF (2) . Using MEDLINE and EMBASE, the authors analyzed 13 reports based on 11 studies on the progression from asymptomatic left ventricular systolic (ALVSD) or diastolic dysfunction (ALVDD) to overt HF. The combined data pertain to a total of 25,369 participants followed for approxi- has reported that she has no relationships relevant to the contents of this paper to disclose. The intervention, which included multistep screening and risk factor modification, reduced the occurrence of asymptomatic LV dysfunction and HF (11) .
RATIONALE FOR SCREENING
For a screening test to be useful, the target condition should cause substantial morbidity, mortality, and health care costs, and the screening test must have satisfactory intrinsic performance (sensitivity, specificity, reproducibility). To yield the optimal positive predictive value, which is the measure that matters clinically, the disease should be prevalent enough in the population screened. The prevalence of asymptomatic LVSD ranges from 2% to 8% of adults depending on the cutoff and with the aforementioned measurement caveats (12) . These numbers will adversely impact the performance of any screening test in the general population. Hence, to be scientifi- Asymptomatic Left Ventricular Dysfunction A P R I L 2 0 1 6 : 2 4 9 -5 1
